Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS (HIK)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 06/19 04:00:03 pm
1406.75 GBp   +1.10%
06/15Mylan expecting another delay for generic Advair
AQ
06/08HIKMA PHARMACEU : Crossing thresholds
CO
06/04HIKMA PHARMACEU : Crossing thresholds
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Drugmaker Hikma's FY profit, revenue meet expectations; shares rise

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/14/2018 | 01:36pm CEST

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) reported full-year profit and revenue largely in line with expectations, aided by strong performance in the second half of the year.

(Reuters) - Hikma Pharmaceuticals Plc reported full-year profit and revenue largely in line with expectations, aided by strong performance in the second half of the year.

The company has struggled due to persistent price pressures in the U.S. market and was forced to cut revenue guidance for its generics business thrice in 2017.

Hikma's problems were further compounded by a delay in the launch of its generic version of GlaxoSmithKline blockbuster lung drug Advair. The U.S. Food and Drug Administration on Monday asked Hikma to conduct a further clinical study evaluating the drug.

Hikma posted 2017 generics revenue of $615 million, surpassing its expectation of about $600 million.

The company, which named former Teva Pharmaceutical generics head Sigurdur Olafsson as its CEO in a bid to improve the business, forecast revenue from generics in 2018 to be in the range of $550 million to $600 million.

"We see these results as reassuring in the context of poor market sentiment and multiple headwinds to the business and would expect a positive reaction," Morgan Stanley analysts wrote in a note.

Hikma shares rose as much as 10.7 percent in early trading.

The Jordan-based drugmaker said earnings before interest, tax, depreciation and amortisation (EBITDA) fell 5 percent to $468 million for the year ended Dec. 31, but was largely in line with analysts' estimate of $469.9 million, according to Thomson Reuters I/B/E/S.

Revenue fell marginally to $1.94 billion, also keeping with estimates.

(Reporting By Justin George Varghese in Bengaluru; Editing by Saumyadeb Chakrabarty and Sunil Nair)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.30% 1547.8 Delayed Quote.17.41%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 1.14% 8779 Delayed Quote.30.84%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
06/15Mylan expecting another delay for generic Advair
AQ
06/08HIKMA PHARMACEUTICALS : Crossing thresholds
CO
06/04HIKMA PHARMACEUTICALS : Crossing thresholds
CO
05/31GRANULES INDIA : commercializes gMethergine
AQ
05/31HIKMA PHARMACEUTICALS : Monthly statement on outstanding equity shares and votin..
CO
05/30HIKMA PHARMACEUTICALS : Crossing thresholds
CO
05/23HIKMA PHARMACEUTICALS : Crossing thresholds
CO
05/18HIKMA PHARMACEUTICALS : AGM Results
PU
05/18Hikma reaffirms full-year revenue forecast, cites better generics business
RE
05/18HIKMA PHARMACEUTICALS : Press Release
CO
More news
News from SeekingAlpha
04/15Longleaf Partners Shareholder Letter Q1 2018 
03/14Hikma Pharmaceuticals' (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnin.. 
03/14Hikma Pharmaceuticals reports FY results 
2017Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2017 Results - Earning.. 
2017Hikma Pharmaceuticals plc. 2017 Q2 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 1 911 M
EBIT 2018 308 M
Net income 2018 185 M
Debt 2018 438 M
Yield 2018 1,72%
P/E ratio 2018 23,70
P/E ratio 2019 20,92
EV / Sales 2018 2,56x
EV / Sales 2019 2,41x
Capitalization 4 461 M
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 16,6 $
Spread / Average Target -10%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Khalid Walid Hosni Nabilsi Chief Financial Officer
Surendera Tyagi Chief Scientific Officer, Global Head-R&D
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS22.66%4 461
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880